Autres langues Foresee Pharmaceuticals Co., Ltd.

Actions

6576

TW0006576002

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
95,5 ^TWD	+0,53 %		+1,60 %	-0,73 %

01/04	Foresee Pharmaceuticals reçoit une recommandation positive du Comité de surveillance des données et de la sécurité pour la poursuite de l'étude Casppian	CI
28/03	Foresee Pharmaceuticals Co. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	02/04
Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study	01/04
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024	15/03
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan	01/12
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment	29/11
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	31/10/23
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA	16/10/23
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients	13/10/23
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	02/10/23
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	02/10/23
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	30/09/23
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039	29/08/23
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee	14/08/23
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference	26/07/23
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing	28/06/23
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases	22/06/23
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member	01/06/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Foresee Pharmaceuticals Co., Ltd.

Actions

6576

TW0006576002

Autres langues

Filtres